Background
HTLV-1 is a neglected retrovirus associated with severe neurological and lymphoproliferative diseases, including tropical spastic paraparesis/HTLV-1-associated myelopathy (HAM/TSP) and adult T-cell leukemia/lymphoma (ATLL). Although Spain is a non-endemic country, more than 550 individuals with HTLV-1 infection had been reported up to date. A national HTLV-1 registry has existed since 1989. Most cases are migrants from endemic regions in Latin America and Equatorial Africa. There is a high diagnostic delay, reflected by a high proportion of cases (22%) presenting with clinical symptoms. Virological factors contributing to HTLV-1 disease progression remain poorly understood.
Methods
Peripheral blood mononuclear cells (PBMCs) from 30 HTLV-1-infected individuals (8 ATLL, 12 HAM/TSP, and 10 asymptomatic carriers) were analyzed. Proviral DNA was sequenced using Next Generation Sequencing (NGS) with 149 biotinylated probes and 1 million reads per sample. Demographic and clinical data including disease status, proviral load, and treatment history were examined along with proviral genomic structure.
Results
The cohort was predominantly female (70%) with a median age of 46 years. Most participants were from Latin America (93%), with one from Ivory Coast and one native Spaniard. Proviral load was significantly higher in ATLL and HAM/TSP patients compared to asymptomatic carriers (median 16.44%, 7.25%, and 4.35%, respectively; p=0.037). No significant differences were found in the number of mutations across structural, accessory, or regulatory genes including tax and HBZ. However, 75% of ATLL patients showed defective proviruses, primarily Type I deletions (loss of gag, pol, and env), associated with acute/lymphoma forms. One patient with a smoldering cutaneous form exhibited a Type II deletion (loss of gag). Post-treatment analysis of two patients revealed partial restoration of deleted proviral regions from a normalized value of 4.2% to 62.1% in one and from 0.2% to 14.5% in another, suggesting clonal replacement or shifts in dominant proviral subpopulations.
Conclusions
Defective HTLV-1 proviruses are significantly associated with ATLL, particularly with aggressive clinical forms. Type I deletions may contribute to oncogenesis and immune evasion. The dynamic nature of proviral structure following treatment highlights the importance of longitudinal genomic sequence monitoring in HTLV-1-infected individuals.